Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:


Targeting EGFR Mutation-positive NSCLC: Critical Advances in Care

Access Activity

Overview / Abstract:

New developments in the role of mutations in the epidermal growth factor receptor (EGFR) gene are transforming the understanding of how NSCLC progresses as a disease. This insight has enabled NSCLC to evolve from an untreatable disease to one where a number of novel therapeutic options are available, and individualized treatment regimens are now offered to optimize care.

This digital flipbook includes pertinent data and video insights into new and practice-changing therapy in the setting of epidermal EGFR mutation-positive NSCLC. Discussion topics include first-line therapy selection, mechanisms of resistance to EGFR TKIs, EGFR TKI therapy beyond progression, and third-generation EGFR TKIs under investigation.

Upon completion of this activity, participants will be able to:
• Select personalized first-line therapy for patients with EGFR mutation-positive NSCLC based on clinical factors and molecular subtyping
• Discuss mechanisms of acquired resistance to EGFR TKI therapy and evidenced-based approaches for selection of sequential therapy in these patients
• Interpret emerging clinical trial efficacy and safety data that will inform application of EGFR TKIs, including comparator trials, novel agents, and combination regimens

This is a targeted activity for physicians to learn about and be updated on new and emerging TKI agents for treatment of NSCLC in the first-, second- and third-line based on the most recent data.


Sep 25, 2019


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME, Radiology / RAD Tech CE, Respiratory Therapy CE


Book, Journal, Monograph, New Procedures, Online, Podcast, Webinar / Webcast / Video, Workbook

Credits / Hours



AMA PRA Category 1 Credit

Is This Activity Certified for "Live" Credit?


Presenters / Authors / Faculty

George R. Simon, MD, FACP, FCCP
Professor of Medicine
Department of Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

H. Jack West, MD
Medical Director, Thoracic Oncology Program
Swedish Cancer Institute
Web Editor, JAMA Oncology
Founder & President
GRACE: Global Resource for Advancing Cancer Education
Seattle, WA

Activity Specialities / Related Topics

Acute Care, Asthma, Education / Teaching, Hematology, Immunology / Immunosuppression, Oncology / Cancer / Radiation Therapy, Pulmonary Medicine / COPD, Radiology / Imagery / Nuclear Medicine, Surgery

Sponsors / Supporters / Grant Providers

Sponsored by the University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL). Supported by an educational grant from Pfizer, Inc.

Keywords / Search Terms

ACHL CME, CE, Continuing Medical Education, CME/CE, NSCLC, lung cancer, tyrosine kinase inhibitors, epidermal growth factor receptor, EGFR, erlotinib, gefitinib, afatinib, osimertinib, dacomitinib, EGF816, nazartinib, olmutinib, ASP8273, lorlatinib, brigatinib, PF-06747775, avitinib, EGFR T790M, EGFR C797S, ACHL, Pfizer, West, Simon, Jack West, George Simon, MD Anderson, UTMDA, MDA Free CE CME Live CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.